Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice

Nai Kong V. Cheung, Bonnie Landmeier, John Neely, A. Dennis Nelson, Carlos Abramowsky, Susan Ellery, Robert B. Adams, Floro Miraldi

Research output: Contribution to journalArticlepeer-review

100 Scopus citations

Abstract

The antibody 3F8, an IgG3 murine monoclonal antibody (MoAb) against disialoganglioside GD2, could target iodine- 131 (131l) to established subcutaneous human neuroblastoma (NB) xenografts in BALB/c nude mice.1311-radiolabeled MoAb (0.125-1 mCi) was injected iv. Tumor radioactivity over time was calculated from scintigraphy, and radiation dose to individual tumors was calculated. Tumor shrinkage occurred only with131 l-labeled 3F8, but not with nonradioactive 3F8 or radiolabeled irrelevant antibody. While the tumor of the control mice enlarged by tenfold, the treated tumor showed over 95% shrinkage by 12 days. Both the rate of shrinkage and duration of tumor response were dose dependent. Calculated doses of more than 10,000 rad could be achieved. Only those tumors that received more than 4,200 rad were completely ablated without recurrence. Recurrent tumors were not antigen negative or radioresistant. These results confirmed the prediction based on imaging studies that human NB xenografts could be effectively eradicated with the use of131l-labeled MoAb 3F8 with tolerable toxicities.

Original languageEnglish (US)
Pages (from-to)739-745
Number of pages7
JournalJournal of the National Cancer Institute
Volume77
Issue number3
DOIs
StatePublished - Sep 1986

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Complete tumor ablation with iodine 131-radiolabeled disialoganglioside G<sub>D2</sub>-specific monoclonal antibody against human neuroblastoma xenografted in nude mice'. Together they form a unique fingerprint.

Cite this